세계의 정맥주사액 시장은 2024년 139억 달러로 평가되어 2025년부터 2034년까지 CAGR 8%로 확대될 것으로 예측되고 있습니다.
정맥주사액은 환자의 혈류에 직접 투여되는 무균의 액체로, 수분 보급의 유지, 약제의 투여, 필수 영양소공급을 목적으로 하고 있습니다. 영양 불량 증가, 만성 질환의 만연, 식량 부족에 의해 수액 수요가 높아지고 있습니다. 세계 인구의 상당수 또한, 신생아 및 소아 의료에서 정맥주사액 사용 증가는 전문적인 영양 보급을 필요로 하는 조산의 다발과 관련되어 있습니다.
이 시장은 유형별로 종합 비경구 영양제와 말초 비경구 영양제(PPN)로 나뉘어져 있습니다. PPN은 영양 균형의 유지, 결핍증의 예방, 경구 섭취가 제한된 환자의 지원에 도움이 됩니다.
| 시장 범위 | |
|---|---|
| 시작 연도 | 2024년 |
| 예측 연도 | 2025-2034년 |
| 시작 금액 | 139억 달러 |
| 예측 금액 | 296억 달러 |
| CAGR | 8% |
시장은 조성별로 세분화되어 비타민 및 미네랄, 탄수화물, 단회 투여 아미노산, 비경구 지질 에멀젼, 기타 필수 화합물이 포함되어 있습니다. 포도당 기반 수액은 영양 보급을 할 수 없는 중증 환자에게의 칼로리 보급에 널리 사용되고 있습니다. 이러한 수액은 대사의 안정성을 유지해, 근육의 분해를 막아, 회복을 돕는데 있어서 중요한 역할을 하고 있습니다.
연령층별로는 노년 인구가 가장 높은 시장 점유율을 차지해, 2024년의 총 매출의 48.8%를 차지했습니다. 효과적인 수분 공급과 영양 공급을 보장하고 만성 질환과 관련된 합병증을 예방합니다.
용도별로 시장은 영양보조, 수혈, 체액 및 전해질 밸런스로 구분됩니다. 영양 불량 발생율 상승, 만성질환, 수술 후 회복 요구가 이 성장에 기여하고 있습니다.
최종 용도별로, 병원 및 진료소가 시장을 독점해, 2024년의 매출 점유율은 58.8%였습니다. 만성 질환의 유병률 증가나 헬스 케어 인프라의 진보가 채용을 한층 더 밀고 있습니다. 또한 진료소에서는 만성 질환의 관리나 단기 치료를 위해 정맥내 치료의 이용이 확대되고 있습니다.
북미에서는 점적 솔루션 시장이 급속히 확대되고 있으며, 미국은 2034년까지 106억 달러에 이를 것으로 예측되고 있습니다.
The Global Intravenous Solutions Market, valued at USD 13.9 billion in 2024, is projected to expand at a CAGR of 8% from 2025 to 2034. Intravenous (IV) solutions are sterile liquids administered directly into a patient's bloodstream to maintain hydration, deliver medications, and supply essential nutrients. Demand for IV solutions is rising due to increasing malnutrition, the prevalence of chronic diseases, and food insecurity. A significant portion of the global population struggles with inadequate nutrition, fueling the need for IV solutions. Additionally, the growing use of IV fluids in neonatal and pediatric care is linked to the high incidence of preterm births, which require specialized nutritional support. Hospitals and healthcare facilities worldwide continue to integrate IV solutions into patient care for hydration therapy, nutrient replenishment, and post-surgical recovery.
The market is divided by type into total parenteral nutrition and peripheral parenteral nutrition (PPN). In 2024, the PPN segment dominated the market, reaching USD 8.4 billion in revenue. PPN is a preferred method for short-term nutritional support, supplying vital nutrients such as dextrose, amino acids, and lipids through peripheral veins. It helps maintain nutritional balance, prevents deficiencies, and supports patients with limited oral intake. Research suggests that timely PPN administration reduces the risk of infections and metabolic complications, making it a crucial component in modern medical treatments.
| Market Scope | |
|---|---|
| Start Year | 2024 |
| Forecast Year | 2025-2034 |
| Start Value | $13.9 Billion |
| Forecast Value | $29.6 Billion |
| CAGR | 8% |
Segmented by composition, the market includes vitamins and minerals, carbohydrates, single-dose amino acids, parenteral lipid emulsions, and other essential compounds. The carbohydrates segment accounted for 40.6% of total market revenue in 2024 and is expected to reach USD 12.2 billion by 2034. Dextrose-based IV solutions are widely used to provide caloric support to critically ill patients who cannot receive nutrition through conventional means. These solutions play a key role in maintaining metabolic stability, preventing muscle breakdown, and aiding recovery. Clinical studies support the effectiveness of carbohydrate-based IV solutions in improving patient outcomes, especially in postoperative and trauma care.
By age group, the geriatric population accounted for the highest market share, representing 48.8% of total revenue in 2024. Older adults are highly susceptible to dehydration due to reduced thirst sensation, mobility challenges, and various health conditions. IV solutions ensure effective hydration and nutrient delivery, preventing complications linked to chronic illnesses. The aging global population further drives demand, with healthcare providers increasingly relying on IV therapy for elderly patients with swallowing difficulties or gastrointestinal disorders.
In terms of application, the market is segmented into nutritional support, blood transfusion, and fluid and electrolyte balance. The nutritional support segment led the market in 2024, generating USD 6.2 billion in revenue. The rising incidence of malnutrition, chronic diseases, and post-surgical recovery needs, contribute to this growth. Patients with gastrointestinal disorders or conditions affecting nutrient absorption benefit significantly from IV-administered nutrition, ensuring adequate nourishment for recovery.
By end use, hospitals and clinics dominated the market, holding a 58.8% revenue share in 2024. These facilities rely heavily on IV solutions for critical care, surgeries, trauma management, and hydration therapy. The increasing prevalence of chronic diseases and advancements in healthcare infrastructure further boost adoption. Additionally, clinics have expanded their use of IV therapy for managing chronic conditions and short-term treatments.
In North America, the intravenous solutions market is witnessing rapid expansion, with the US projected to reach USD 10.6 billion by 2034. Rising healthcare demands, stringent FDA regulations ensuring product quality, and high adoption rates of advanced IV solutions contribute to market growth. With ongoing advancements and increasing awareness of IV therapy's benefits, the market is poised for significant expansion in the coming years.